Tonix Pharmaceuticals, through its subsidiary Tonix Medicines, has completed its asset purchase agreement with Upsher Smith Laboratories for assets relating to Upsher's Zembrace SymTouch and Tosymra products. The $15 million transaction includes a $100,000 - $150,000 monthly transition service contract for the first nine months.